JILLIAN CROWLEY: Open Payments
NPI 1992902977 · BLOOMFIELD, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,287 in 49 payments from 15 companies in 2025. Trend: 2023 $1,295 · 2024 $1,446 · 2025 $1,287
Food & beverage: $1,287
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 6 | $186 |
| E.R. Squibb & Sons, L.L.C. | 13 | $171 |
| Medtronic, Inc. | 1 | $159 |
| Abbott Laboratories | 1 | $145 |
| Alnylam Pharmaceuticals Inc. | 4 | $119 |
| PFIZER INC. | 5 | $117 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $80 |
| AstraZeneca Pharmaceuticals LP | 4 | $79 |
| Novo Nordisk Inc | 4 | $72 |
| Amgen Inc. | 2 | $48 |
Products named: LEQVIO, SYMPLICITY G3, CARDIOMEMS, CAMZYOS, VYNDAQEL, JARDIANCE, ELIQUIS, Wegovy.
Industry payments across CT — which companies pay providers there.
